|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.38 - 0.51|
|52 Week Range||0.26 - 2.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 4 cents. The biopharmaceutical company posted revenue of $304,000 in the period. The company's shares closed at 41 cents. ...
THE WOODLANDS, Texas, Nov. 13, 2017-- Repros Therapeutics Inc. ® today announced financial results for the third quarter ended September 30, 2017.. Net loss for the three month period ended September 30, ...
Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
CORAL GABLES, FL / ACCESSWIRE / October 9, 2017 / So far this year, the SPDR S&P Biotech ETF (XBI) has jumped 49% to its highest levels in over two years , though some investors believe the move isn't ...
NEW YORK, NY / ACCESSWIRE / October 9, 2017 / U.S. markets pulled back Friday as data showed U.S. nonfarm jobs declined for the first time in seven years. The Dow Jones Industrial Average declined 0.01 ...
The The Woodlands, Texas-based company said it had a loss of 8 cents per share. The biopharmaceutical company posted revenue of $7,000 in the period. The company's shares closed at 35 cents. A year ago, ...
Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.
NEW YORK , July 24, 2017 /PRNewswire/ -- Acacia Communications, Inc. (ACIA) Lifshitz & Miller announces investigation on behalf of ACIA investors concerning whether ACIA issued misleading statements about ...
Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Repros Therapeutics Inc. .
NEW YORK , July 17, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repros Therapeutics Inc. ("Repros" ...
NEW YORK, July 17, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repros Therapeutics, Inc. ("Repros" or the "Company") (NASDAQ: RPRX). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980. On this news, Repros's share price has fallen more than 30% during intraday trading on July 17, 2017.
On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 22 cents. The biopharmaceutical company posted revenue of $7,000 in the period. In the final minutes of trading on Tuesday, ...
Repros Therapeutics Inc. (RPRX) is expected to report first-quarter 2017 results this month. Let's see how things are shaping up for this quarter.
Repros Therapeutics (RPRX) announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data related to the effect of the same on the liver